Summary

The global incretin-based drugs market was valued at $34.3 billion in 2022, and is projected to reach $73.9 billion by 2032, registering a CAGR of 7.9% from 2023 to 2032. Incretins are a group of gastrointestinal polypeptides that control insulin production in pancreatic beta cells. Incretins are essential for the regulation of insulin production and the metabolism of glucose in the body, especially after food intake. Glucagon-like peptide-1 or GLP-1 is a hormone secreted by the digestive tract in response to food. It stimulates insulin secretion from the pancreatic beta cells and helps to lower blood glucose levels after meals. These incretins release insulin not only when blood glucose levels rise but also when glucose levels are expected to rise, helping to regulate glucose levels. However, these incretin hormones are rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4), which decreases their effectiveness and duration of action in the body.
To enhance the action of incretins in managing type 2 diabetes, pharmaceutical approaches include the use of DPP-4 inhibitors and GLP-1 analogues. The DPP-4 inhibitors work by blocking DPP-4 activity. These drugs increase the levels of circulating glucagon-like peptides (GLP-1) and gastric inhibitory peptide (GIP). These hormones have a longer-lasting effect on insulin secretion and glucose regulation. On the other hand, synthetic GLP-1 drugs are GLP-1 transporters that are more tolerant to DPP-4 degradation. They work by mimicking the action of natural GLP-1. These drugs increase insulin release, inhibit glucagon secretion, slow gastric emptying, and reduce appetite.

The growth of incretin-based drugs market is mainly attributed to the high prevalence of type 2 diabetes population around the globe. Type 2 diabetes is a condition in which blood sugar levels are too high and the body is not able to produce enough insulin. The number of people with type 2 diabetes is on the rise, due to the rise in obesity around the world. Diabetes mellitus (Type 2) is currently treated using incretin-based drugs. These drugs control glucose metabolism in a variety of ways, are associated with low levels of hypoglycemia, and either do not affect body weight or do not stimulate weight loss. Thus have a huge demand in the treatment of this condition, which propels the growth of the incretin-based drugs market.
In addition, incretin-based drugs have shown promising results in weight loss or weight neutrality. This makes them attractive to a wider patient base interested in obesity management. Furthermore, ongoing R&D efforts to enhance the effectiveness, safety, and delivery mechanisms of the incretin-based therapies have also contributed to market expansion. The growing knowledge of the biology behind incretin and its impact on various metabolic disorders continue to drive innovation. This is anticipated to drive the market for incretin-based drugs in coming years.

However, the high cost of the treatment and regulatory challenges may hamper market growth to some extent. Incretin based drugs are usually more expensive than traditional diabetes drugs. Cost becomes a major issue, especially in areas where healthcare costs are high, which may limit access to these drugs. Also, the market is affected by stringent regulations and approval procedures by regulatory bodies such as the Food and Drug Administration (FDA) in the U.S. and the European Medicines Agency (EMA) in Europe. Delays or complexity in the approval of new drugs or indications may impede market growth.
The incretin-based drugs market is segmented on the basis of drug class, route of administration, distribution channel, and region. On the basis of drug class, the market is divided into GLP-1 receptor agonists and DPP-4 inhibitors. On the basis of route of administration, the market is classified into oral and parenteral. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players profiled in this report are Eli Lilly and Company., Merck & Co., Inc., GlaxoSmithKline plc, Sanofi, Sun Pharmaceutical Industries Ltd., Lupin, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, AstraZeneca plc and Takeda Pharmaceutical Company Ltd.

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the incretin-based drugs market analysis from 2022 to 2032 to identify the prevailing incretin-based drugs market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the incretin-based drugs market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global incretin-based drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Additional company profiles with specific to client's interest
● Additional country or region analysis- market size and forecast
● Average Selling Price Analysis / Price Point Analysis
● Brands Share Analysis
● Criss-cross segment analysis- market size and forecast
● Expanded list for Company Profiles
● Historic market data
● Import Export Analysis/Data
● Key player details (including location, contact details, supplier/vendor network etc. in excel format)
● List of customers/consumers/raw material suppliers- value chain analysis
● Market share analysis of players at global/region/country level
● Per Capita Consumption Trends
● Product Consumption Analysis
● Reimbursement Scenario
● SWOT Analysis
● Volume Market Size and Forecast
Key Market Segments
By Drug Class
● GLP-1 receptor agonists
● DPP-4 inhibitors
By Route of Administration
● Oral
● Parenteral
By Distribution Channel
● Hospital Pharmacies
● Drug Stores and Retail Pharmacies
● Online Providers
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ Eli Lilly and Company.
○ Takeda Pharmaceutical Company Ltd.
○ Lupin
○ Novartis AG
○ Merck & Co., Inc.
○ Sun Pharmaceutical Industries Ltd.
○ Boehringer Ingelheim International GmbH
○ Sanofi
○ Novo Nordisk A/S
○ AstraZeneca plc

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rising prevalence of type-2 diabetes
3.4.1.2. Recent product approvals and product launches in the market
3.4.1.3. Recent advancement in Incretin-Based Pharmacotherapies
3.4.2. Restraints
3.4.2.1. High cost of incretin-based drugs
3.4.2.2. Stringent regulations related to medications
3.4.3. Opportunities
3.4.3.1. Surge in research and development in incretin-based drugs
CHAPTER 4: INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. GLP-1 receptor agonists
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. DPP-4 inhibitors
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Parenteral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Oral
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: INCRETIN-BASED DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Drug Class
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Drug Class
7.2.5.1.2. Market size and forecast, by Route of Administration
7.2.5.1.3. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Drug Class
7.2.5.2.2. Market size and forecast, by Route of Administration
7.2.5.2.3. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Drug Class
7.2.5.3.2. Market size and forecast, by Route of Administration
7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Drug Class
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Drug Class
7.3.5.1.2. Market size and forecast, by Route of Administration
7.3.5.1.3. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Drug Class
7.3.5.2.2. Market size and forecast, by Route of Administration
7.3.5.2.3. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Drug Class
7.3.5.3.2. Market size and forecast, by Route of Administration
7.3.5.3.3. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Drug Class
7.3.5.4.2. Market size and forecast, by Route of Administration
7.3.5.4.3. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Drug Class
7.3.5.5.2. Market size and forecast, by Route of Administration
7.3.5.5.3. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Drug Class
7.3.5.6.2. Market size and forecast, by Route of Administration
7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Drug Class
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Drug Class
7.4.5.1.2. Market size and forecast, by Route of Administration
7.4.5.1.3. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Drug Class
7.4.5.2.2. Market size and forecast, by Route of Administration
7.4.5.2.3. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Drug Class
7.4.5.3.2. Market size and forecast, by Route of Administration
7.4.5.3.3. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Drug Class
7.4.5.4.2. Market size and forecast, by Route of Administration
7.4.5.4.3. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Drug Class
7.4.5.5.2. Market size and forecast, by Route of Administration
7.4.5.5.3. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Drug Class
7.4.5.6.2. Market size and forecast, by Route of Administration
7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Drug Class
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Drug Class
7.5.5.1.2. Market size and forecast, by Route of Administration
7.5.5.1.3. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Drug Class
7.5.5.2.2. Market size and forecast, by Route of Administration
7.5.5.2.3. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Drug Class
7.5.5.3.2. Market size and forecast, by Route of Administration
7.5.5.3.3. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Drug Class
7.5.5.4.2. Market size and forecast, by Route of Administration
7.5.5.4.3. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Eli Lilly and Company.
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Merck & Co., Inc.
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Takeda Pharmaceutical Company Ltd.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. AstraZeneca plc
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Sanofi
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Sun Pharmaceutical Industries Ltd.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Lupin
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Novo Nordisk A/S
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Boehringer Ingelheim International GmbH
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Novartis AG
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance